On Tuesday ITV news announced that a malaria vaccine, developed by GlaxoSmithKline (GSK), and trialled in Ghana, has almost halved the number of cases of malaria in children and could be for sale in Africa within a year.
According to ITV, GSK said it is planning to release the drug to market at the reduced price of $5 per vaccine. Although this cost is still expensive for millions across the Sub-Saharan region, it is relatively cheap and a major breakthrough in the fight against this costly, deadly disease.
The trial is one of the biggest ever undertaken and the results show that the vaccine could save millions of lives each year. 15,000 people took part in it, across seven African countries, including Ghana, Kenya, Tanzania, Malawi and Mozambique.
Professor Tsiri Agbenyega told Lawrence McGinty, from ITV news that they ‘have reached a “eureka moment” in the development of just such a vaccine – the first in the world against a parasite.’ His hospital in Agogo is one of 11 centres where trials of the malaria vaccine are being carried out.
Although the full results are not yet available, the results are encouraging at this half-way point, as the vaccine nearly halves the number of episodes of malaria in children aged between 17 months and 5 years. For every 1,000 children vaccinated, 941 cases of clinical malaria were prevented over 18 months of follow-up.
You can read more about it on ITV news here.